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Abstract
Introduction: Breast tumor kinase (Brk/protein tyrosine kinase 6 (PTK6)) is a nonreceptor, soluble tyrosine kinase
overexpressed in the majority of breast tumors. Previous work has placed Brk downstream of epidermal growth
factor receptor (ErbB) activation and upstream of extracellular signal-regulated kinase 5 (ERK5) and p38 mitogen-
activated protein (MAP) kinases. Herein we investigate the regulation of Brk kinase activity and cell migration in
response to treatment of keratinocytes (HaCaT cells) and breast cancer cell lines (MDA-MB-231 and T47D cells) with
hepatocyte growth factor (HGF) and macrophage stimulating protein (MSP), peptide ligands for Met and Ron
receptors, respectively.
Methods: In vitro kinase assays were performed to directly measure Brk kinase activity in response to MET and
RON ligands. Transfection of Brk-targeted RNAi was used to knock down endogenous Brk or ERK5 in multiple cell
lines. Kinase activities (downstream of MET signaling) were assayed by Western blotting using total and phospho-
specific antibodies. Boyden chamber assays were used to measure cell migration in response to manipulation of
Brk and downstream MET effectors. Rescue experiments were performed by knock down of endogenous Brk using
RNAi (targeting the untranslated region (3′-UTR)) and transient transfection (re-expression) of either wild-type or
kinase-inactive Brk.
Results: Brk gene silencing revealed that HGF, but not MSP, induced robust Brk-dependent cell migration. Brk and
ERK5 copurified in HGF-induced protein complexes, and Brk/ERK5 complexes formed independently of Brk kinase
activity. ERK5 was required for breast cancer cell but not keratinocyte cell migration, which became ERK1/2-
dependent upon ERK5 knockdown. Notably, rescue experiments indicated that the kinase activity of Brk was not
required for HGF-induced cell migration. Further, expression of either wild-type or kinase-inactive Brk in Brk-null
MDA-MB-435 cells activated ERK5 and conferred increased HGF-induced cell migration.
Conclusions: These results have identified Brk and ERK5 as important downstream effectors of Met signaling to
cell migration. Targeting ERK5 kinase activity or inhibiting the formation of Brk/ERK5 complexes may provide an
additional means of blocking cell migration associated with breast cancer progression to metastasis.
Introduction
Breast tumor kinase (Brk), also termed protein tyrosine
kinase 6 (PTK6), was cloned from a human metastatic
breast tumor and is a member of a novel family of solu-
ble or nonreceptor PTKs with approximately 56%
homology to the kinase domain of c-Src [1]. Similar to
c-Src, Brk contains tandem N-terminal src homology
3( S H 3 )a n ds r ch o m o l o g y2( S H 2 )d o m a i n sa n da
C-terminal protein kinase domain [1]. However, Brk
does not appear to be myristoylated and is present in
both the cytoplasm and nucleus, but differentially
localized in a cell type-specific manner. Membrane-
associated Brk has recently been linked to oncogenic
actions in human embryonic kidney (HEK)-293 cells [2].
Brk is undetectable in normal mammary gland. How-
ever, it is overexpressed in a majority of human breast
tumors and breast cancer cell lines [3-6]. In addition to
human breast tumors, elevated Brk expression has also
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lymphoma [9] and ovarian cancer cell lines [10]. Brk is
present in the nuclei of normal prostate cells and well-
differentiated prostate cancer cells, but mislocalized
(more cytoplasmic) in undifferentiated or aggressive
prostate cancer cells [11].
A small number of cytoplasmic and nuclear Brk sub-
strates have been identified and include adaptor proteins
(breast kinase substrates-1 and -2, paxillin, IRS-4, GAP-
A.p65), transcription factors (STAT3/5) and RNA-inter-
acting proteins (src-associated during mitosis (Sam68)
and SLM-1/2), including nucleic acid binding protein
( P S F )[ 1 2 - 1 8 ] .T h ef i r s ti d e n t i f i e ds u b s t r a t ef o rB r k
phosphorylation in vivo was Sam68 (Src-associated dur-
ing mitosis, 68 kDa) [15]. Brk-dependent phosphoryla-
tion of Sam68 on tyrosine negatively regulates its RNA-
binding function [15,19].
Brk expression in normal tissues is largely confined to
differentiating epithelial cells of the gastrointestinal tract
and skin, as well as secretory epithelial cells of the pros-
tate [7,11,20]. The murine ortholog of Brk, Sik (Src-like
intestinal kinase), is expressed in a similar pattern. Brk
appears to sensitize nontransformed cells to apoptosis
[21,22]. Sik-knockout mice exhibit elongated intestinal
villi associated with activated AKT and reduced apopto-
sis [20,23]. Brk also appears to inhibit basal AKT activity
in selected nontumorigenic cell line models, such as
COS-1 cells, but not in T47D breast cancer cells [24].
Previous evidence primarily derived from cancer cell
models supports the involvement of Brk as a novel
downstream effector of epiderman growth factor recep-
tor (EGFR) and other ErbB family member receptor sig-
naling networks [24,25]. Brk expression in HB4a
(human mammary luminal epithelial cells) leads to
increased phosphoinositide 3-kinase (PI3K) activity via
epidermal growth factor (EGF)-induced ErbB3 phos-
phorylation and the recruitment of p85 PI3K to ErbB3
receptors [26]. In addition, EGF and heregulin-b1a c t i -
vate Brk in T47D breast cancer cells [25]. Studies using
T47D cells stably expressing Brk shRNA demonstrated
that Brk was required for heregulin-b1-induced activa-
tion of Rac1, p38 and extracellular signal-regulated
kinase 5 (ERK5) mitogen-activated protein kinases
(MAPKs), and increased cyclin D1 expression [25].
Further studies linked Brk signaling to p38 MAPK
activation as required steps for EGF and heregulin-b1-
induced T47D breast cancer cell migration [25]. The
role of ERK5 was not examined in these studies.
A s i d ef r o ms t u d i e sf o c u s e do ne r b Br e c e p t o ra c t i o n ,
regulation of Brk signaling remains largely undefined and
appears to occur in a cell type-specific manner. Herein
we sought to identify additional growth factor receptor-
mediated signaling pathways associated with Brk regula-
tion. Our search identified Brk as a downstream effector
of Met, a transmembrane receptor tyrosine kinase which
consists of 145 kDa b- and 50 kDa a-subunits. Activation
of the Met receptor by its ligand, hepatocyte growth fac-
tor (HGF), has been shown to induce increased cell
migration of keratinocytes and is implicated in cancer
metastasis [27]. The Met oncogene is frequently overex-
pressed in human solid tumors. In normal tissues, it is
predominately expressed in epithelial cells and endothe-
lial cells in vivo and in epithelial cell lines in vitro
[28-30]. The main physiological function of Met is to
serve as a receptor for HGF [29,30].
Activation of Met receptors via HGF binding pro-
motes tyrosine phosphorylation of its intracellular b-
chain domain and the recruitment of signaling protein
complexes required for the activation of downstream
signaling pathways. HGF is a mesenchymal cytokine
produced mainly by fibroblasts, macrophages, and
smooth muscle cells [30]. HGF is involved in prolifera-
tion, angiogenesis, branching morphogenesis, and matrix
invasion and possesses both mitogenic and motogenic
properties [30]. Breast cancers frequently exhibit dysre-
gulation of HGF and Met signaling, ultimately resulting
in increased tumor growth and invasion [31].
In addition to its role as a motility and invasion-indu-
cing factor for cancer cells of epithelial origin, HGF has
also been shown to contribute to the migration of nor-
mal keratinocytes during wound healing. Herein we
demonstrate that Brk mediates HGF-induced cell migra-
tion downstream of Met receptors in both breast cancer
cells and keratinocytes. In breast cancer cells, this
occurs via an ERK5-dependent pathway and is indepen-
dent of Brk kinase activity. These results provide insight
into a potential mode of Brk action in metastatic breast
cancer cells; we conclude that Brk/ERK5 complexes are
key mediators of the migratory response to HGF. Stimu-
lation of Brk-dependent Met signaling may also aid in
wound healing related to skin injury. Targeting a similar
pathway in breast cancer cells, perhaps by inhibition of
ERK5 kinase activity or disruption of Brk/ERK5 com-
plexes, may provide an effective means of blocking
breast cancer metastasis.
Materials and methods
Cell culture
T47D cells were maintained in minimum essential med-
ium (Gibco, Carlsbad, CA) supplemented with 10 μg/ml
insulin, 1× nonessential amino acids, 1× penicillin/strep-
tomycin, and 5% fetal bovine serum (FBS). MDA-MB-
231 cells were maintained in Dulbecco’sm o d i f i e d
Eagle’s medium (DMEM; Gibco) supplemented with 5%
FBS, 1× penicillin/streptomycin, and 10 μg/ml insulin.
HaCaT and COS cells were maintained in DMEM
(Gibco) supplemented with 10% FBS and 1× penicillin/
streptomycin. MDA-MB-435 cells were cultured in
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lin/streptomycin and 10 μg/ml insulin.
Antibodies and reagents
Phosphotyrosine antibodies (4G10) were purchased from
Upstate Biotechnology, Inc. (Temecula, CA) and used at
1:1000 in phosphate-buffered saline Tween (PBST). Brk
antibodies (Lots B0604/D0704) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA) and used at
1:1000 in 1% milk. Total antibodies to p38, AKT, Erk1/2,
ERK5 and Met were purchased from Cell Signaling Tech-
nology (Danvers, MA) and used at 1:1000 in 1% milk.
Phospho-antibodies to p38 (Thr180/Tyr182), phospho-
Akt (ser473), phospho-ERK5 (Thr218/Tyr220), phospho-
Erk1/2 (Thr202/Tyr204), and phospho-Met (1234/1235)
were purchased from Cell Signaling and used at 1:1000 in
1% bovine serum albumin (BSA), except phospho-Erk1/2,
phospho-Met, and phospho-ERK5 were used at 1:1000 in
1% milk. Purified heregulin-b1 was purchased from
Upstate Biotechnology, Inc. EGF was used at 20 ng/ml
and purchased from Sigma (St. Louis, MO); HGF was
used at 50 ng/ml and purchased from Millipore (Billerica,
MA); and MSP was used at 80 ng/ml and purchased from
R&DS y s t e m s( M i n n e a p o l i s ,M N ) .T h eM e ki n h i b i t o r
(U0126) was purchased from Calbiochem (Gibbstown,
NJ). Wt and km-Brk were transiently transfected into
COS and MDA-MB-435 cells with Fugene 6 (Roche
Indianapolis, IN).
Brk siRNA
Brk (PTK6) siGenome SMARTpool duplex and Brk
(PTK6) custom duplex targeting the Brk untranslated
region (3′-UTR) were purchased from Dharmacon
(Lafayette, CO) and transiently transfected into T47D,
MDA-MB-231 or HaCaT cells at 50-100 nM with Effec-
tene according to the manufacturer’si n s t r u c t i o n s( Q i a -
gen, Valencia, CA). Brk rescue experiments were
performed by transiently cotransfecting cells with Brk
small interfering RNA (siRNA) targeting the 3′-UTR or
Brk mRNA and either flag-tagged vector (pCMV), flag-
tagged wt-Brk or flag-tagged km-Brk (lacking the Brk
3′-UTR). Nonsilencing siRNA and flag-tagged (empty)
vector were cotransfected as a control.
Brk kinase assay
T47D and MDA-MB-231 breast cancer cells, and
HaCaT keratinocyte cells were serum starved for 24 hr
and treated with 50 ng/ml HGF at various time points.
Brk kinase assays were performed as described pre-
viously [25].
Cell migration assay
Modified Boyden chamber migration assays were per-
formed using a 10-well or 48-well chamber. Boyden
chamber migration assays using a 10-well chamber were
performed as described previously [25]. T47D, MDA-
MB-231, MDA-MB-435 and HaCaT cells were seeded at
3×1 0
5 in 60 mM dishes. The following day cells were
transiently transfected with 50-100 nM of Brk siRNA.
Three days posttransfection,c e l l sw e r et r y p s i n i z e d ,
washed two times in serum-free media and then resus-
pended at 1 × 10
5 cells/ml in serum-free media contain-
ing 10 μg/ml collagen type I human placenta
(Calbiochem). Thirty microliters of serum-free medium
containing 10 μg/ml collagen I with or without 50 ng/ml
HGF or 80 ng/ml machrophage stimulating protein was
added to the lower chamber. A polycarbonate 12 μM
pore membrane (Neuroprobe, Gaithersburg, MD) was
placed between the lower and upper chambers. Cells
(0.05 ml) were then added to the upper chamber. Intact
chambers were incubated at 37°C, 5% CO2 for 6 hr. At
the end of the incubation period, cells remaining in the
upper chamber were removed with a cell scraper. The
cells that migrated through the membrane were fixed
and stained with HEMA3 staining kit (Fisher Scientific,
Kalamazoo, MI). The membrane was then mounted on a
glass slide, and the cells were counted at ×40 magnifica-
tion using a light microscope. Samples were plated in tri-
plicate, and three fields per well were counted. The
results are representative of three individual experiments.
Coimmunoprecipitations
HaCaT, MDA-MB-231, and COS-1 cells were serum
starved for 24 hr and treated with 50 ng/ml of HGF at
various time points. The cells were lysed in RIPA Lite
buffer (5 M NaCl, 0.5 M Na2HP04,0 . 5MN a H 2P04,0 . 5
M EDTA, 1% Triton X, 1 M NaF, 0.2 M Na3V04,2m g /
ml aprotinin, 1 M BGP, 0.1 M PMSF, b-Me, and pro-
tease inhibitor cocktail tablet). ERK5 protein was
immunoprecipitated from 1 mg total whole cell lysate
using 1 μg ERK5 antibody conjugated to protein G-agar-
ose beads (Roche). For the conjugation step, 1 μgE R K 5
antibody or normal rabbit IgG control antibody was
incubated with 30 μl protein G-sepharose for 1-2 hr at
4°C and washed three times with lysis buffer. ERK5
immunoprecipitations were incubated at 4°C for 3-4 hr.
Next, immunocomplexes were washed with lysis buffer
four times. The samples were resuspended in 50 μll y s i s
buffer and 15 μl 5× Laemmli sample buffer. Samples
were boiled for 5 min and then separated by SDS-PAGE
and transferred to PVDF (polyvinylidene fluoride) mem-
branes for Western blot analysis. Brk or Flag (Sigma)
specific antibodies were used for Western blotting.
Results
Brk mediates Met receptor signaling to ERK5
Previous reports have focused primarily on Brk kinase
activity downstream of erbB family member receptor
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receptors that may act upstream of Brk in normal and
neoplastic cell contexts, we considered the Met receptor,
which has been implicated in wound healing in skin
cells and in cancer cell metastasis [27]. HaCaT (human
keratinocytes) and MDA-MB-231 and T47D breast can-
cer cells were utilized as models. These cell lines coex-
press Brk and Met receptors and represent a spectrum
of transformed and invasive properties; MDA-MB-231
cells are highly invasive relative to T47D cells, whereas
HaCaT cells are immortalized but model “normal” or
nontumorigenic skin.
Cultures were serum starved for 24 hr and either vehicle
treated or treated with HGF for 15, 30 and 60 min. Brk
was immunoprecipitated from whole cell lysates using
Brk-specific antibodies and subjected to in vitro kinase
reactions containing exogenously added ATP and recom-
binant Sam68 as a Brk-substrate as previously defined
[25]. Brk kinase activity as measured by Brk autopho-
sphorylation and phosphorylation of its substrate, Sam68,
was determined by Western blotting using a pan antipho-
sphotyrosine (4G10) antibody. Rabbit IgG was included as
a specificity control for the IP-kinase assay. In HaCaT cells
(Figure 1a), Brk exhibited weak basal activity in vehicle-
treated cells relative to elevated and sustained activation
throughout the HGF-induced time course. Brk autopho-
sphorylation and in vitro Sam68 phosphorylation were
heightened at 60 min relative to early time points (lane 4).
Densitometry of bands representing phosphorylated pro-
teins indicated a consistent time-dependent increase in
Brk autophosphorylation and phosphorylation of Sam68
in HGF-treated HaCaT cells. Similar results were observed
in MDA-MB-231 cells; Brk was robustly activated in
response to 15-60 min of HGF exposure as measured by
increased autophosphorylation of immunopurified Brk
and increased phosphorylation of recombinant Sam68 in
vitro (Figure 1b). In contrast, we observed high basal Brk
activity in serum-starved T47D breast cancer cells cultured
in the absence of HGF (Figure 1c). These cells appear rela-
tively insensitive to HGF treatment; we typically observed
a modest increase in Brk kinase activity, as measured by
phosphorylation of Sam68 in vitro at 15 min of HGF treat-
ment (Figure 1c). Equal levels of Brk were immunoprecipi-
tated in Brk IPs; Brk was not present in IgG specificity
controls. These results indicate that the Met receptor
ligand, HGF, is able to activate Brk kinase activity in both
keratinocytes and breast cancer cells. However, selected
breast cancer cells (e.g., T47D) may contain elevated basal
levels of activated Brk [25].
We previously showed that Brk is required for EGF-
and heregulin-induced activation of ERK5 and p38
MAPK in breast cancer cells [25]. Having established
that Brk kinase activity is sensitive to HGF, we per-
formed Brk knockdown studies to investigate whether
Figure 1 HGF activates Brk. (a). In vitro kinase assays were
performed using HaCaT cells. Serum-starved HaCaT cells were
treated with either vehicle (water) or 50 ng/ml HGF for 15 to 60
min. Whole cell lysates were subjected to Brk immunoprecipitation
and in vitro kinase assays using purified recombinant Sam68 as a
substrate. Densitometry of bands represent phosphorylated Brk and
Sam68 proteins indicated by arbitrary units (a.u.). Brk kinase assays
were performed under similar conditions and treatments as in (a)
using MDA-MB-231 (b) and T47D (c) breast cancer cells.
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ways. A pool of siRNA was used to silence Brk expres-
sion in HaCaT and MDA-MB-231 cells (Figure 2). Cells
were transiently transfected with either negative control
or Brk siRNA. Serum-starved cells were then treated
with either vehicle or HGF for 15, 30 or 60 min and
whole cell lysates were analyzed by Western blotting
with phospho-specific and total antibodies recognizing
AKT, ERK5, ERK1/2, p38 MAPK, and Brk (Figure 2).
EGF was included as a positive control for robust activa-
tion (15 min) of these kinases. HGF induced activation
of AKT, ERK5 and ERK1/2 at 15-60 min in both
HaCaT (Figure 2a) and MDA-MB-231 cells (Figure 2b).
No significant changes in activation of p38 MAPK were
observed upon HGF treatment of HaCaT cells (Figure
2a) or breast cancer cell lines (not shown); p38 MAPK
was not further studied herein (except when included as
a loading control). In HaCaT cells expressing Brk
siRNA, phospho-AKT levels remained relatively
unchanged compared to controls and throughout the
HGF time course. Similarly, in MDA-MB-231 cells, Brk
knockdown did not appreciably alter AKT activity in
response to HGF, but increased AKT activity following
EGF (Figure 2b; compare lane 5 to lane 10). These
results are consistent with our previous report that Brk
inhibits AKT in selected (nontransformed) cell lines [24]
and studies in Sik-knockout mice, which display
increased AKT activity in tissues that normally express
Sik, the mouse homolog of Brk [23]. Notably, both HGF
and EGF activated ERK5 at 15-60 min, as measured by
either phospho-specific antibodies (recognizing Thr218
and Tyr220) or by the gel “upshift” in total ERK5. ERK5
phosphorylation, as measured using phospho-specific
antibodies (Figure 2b; lanes 2-4 and 7-9) often precedes
(or is separable from) gel upshift of a portion of the
band representing total ERK5, which is likely due to
multisite phosphorylation at sites other than (or in addi-
tion to) Thr218/Tyr220 [25,32]. Expression of Brk
siRNA blocked growth factor (HGF and EGF) induced
ERK5 activation (most apparent at 30-60 min) relative
to control siRNA. We detected no consistent differences
in the ability of these growth factors to activate ERK1/2
or in the levels of basal p38 MAPK activity in cells
expressing Brk siRNA relative to control siRNA. These
results suggest that Brk primarily mediates Met receptor
signaling to ERK5 in breast cancer cells and keratino-
cytes. Brk appears to be a weak negative regulator of
AKT in some cell contexts (Figure 2) [24,33].
Brk mediates HGF-induced cell migration
To determine whether Brk is required for HGF-induced
cell migration in vitro, we performed Boyden chamber
migration assays (Figure 3). In this assay, cells migrate
from upper to lower chambers separated by cell-
permeable membranes. HGF was added to the lower
chamber as a chemoattractant for cells plated in the
upper chamber. Cells that appear in the lower chamber
over time (6 hr) are counted as a measure of induced
cell migration. EGF (20 ng/ml) was used as a positive
control for growth factor-induced cell migration. Both
HaCaT and MDA-MB-231 cells demonstrated EGF and
HGF-induced increases in migration compared to vehi-
cle-treated control cells (Figures 3a and 3b). Similar to
EGF, HGF-induced migration was attenuated in Brk
siRNA-expressing cells relative to control cells, indicat-
ing a requirement for Brk in Met receptor-induced cell
migration. T47D breast cancer cells were also subjected
Figure 2 Brk mediates Met receptor signaling to ERK5. HaCaT
(a) and MDA-MB-231 (b) cells were transiently transfected with a
nontargeting siRNA (control) or Brk siRNA and serum-starved for 24
hr. Cells were then treated with vehicle (water) or 50 ng/ml HGF for
15 to 60 min. Whole cell lysates were harvested and subjected to
Western blotting with phospho- and total-specific antibodies to
AKT, ERK5, ERK1/2, p-38, and total Brk. Cells were stimulated with 20
ng/ml EGF for 15 min as a positive control for kinase activation.
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of these findings (Figure 3c). Although these cells are
weakly responsive to HGF-induced Brk kinase activation
(Figure 1c), their HGF-induced migration is predomi-
nantly Brk-dependent.
Signaling specificity of Brk-dependent cell migration
To further establish the requirement of Brk in HGF-
i n d u c e dc e l lm i g r a t i o nw ef i r s tw a n t e dt od e m o n s t r a t e
the specificity of our findings (Figure 3). The Met family
member, Ron, is a receptor tyrosine kinase that mediates
actions similar to those of the Met receptor. However,
these receptors differ in ligand-binding specificity.
Macrophage-stimulating protein (MSP) is a highly speci-
fic Ron ligand and does not activate Met signaling
[34,35]. To measure the relative levels of Met and Ron
gene expression in these cell lines, quantitative real-time
PCR was performed (Figure 4a). Ron mRNA levels are
similar in T47D and HaCaT cells, but greatly reduced in
MDA-MB-231 cells. Notably, HaCaT and MDA-MB-
231 cells have similar high levels of Met gene expression
as measured by both RNA and protein (Figure 4a, inset).
However, T47D cells express significantly less Met
mRNA and protein in comparison to the other two cell
lines, perhaps in part explaining their relative insensitiv-
ity to HGF. Although T47D cells contain ~10-fold less
Met receptor relative to HaCaT and MDA-MB-231
cells, these cells are able to robustly activate ERK5 in
response to HGF (5-30 min), indicating a fully func-
tional Met signaling pathway (Figure 4b). Additionally,
by increasing the sensitivity of our Brk in vitro kinase
assay, we detected Brk kinase activity (in vitro phosphor-
ylation of Sam68) following only 10 min of HGF expo-
sure (20-50 ng/ml) while Brk autophosphorylation
remained high in lysates from untreated cells (Figure
4c). In contrast to T47D cells that signal to ERK5 in
response to either HGF or MSP (in the face of low
mRNA expression for both receptors), both HaCaT and
MDA-MB-231 cells failed to respond to MSP over a
90-min time course, while HGF remained a potent
input to ERK5 activation (Figure 4b), perhaps reflective
of their low levels of Ron relative to Met receptor
mRNA (Figure 4a).
Because HaCaT cells express measurable levels of
Met, Ron and Her2 (our positive control), we tested the
specificity of these receptors as upstream inputs to Brk
activation under the same conditions by performing
additional in vitro kinase assays (Figure 5a). When
added to serum-starved HaCaT cells, all three ligands
(HGF, MSP and heregulin; 15 min) activated Brk autop-
hosphorylation and increased phosphorylation of Sam68
in vitro. Similar levels of Brk were immunopurified from
Brk lysates (10% input) and IgG controls were clean.
These data demonstrate that MSP, when added to cells
that express appreciable levels of Ron receptor, can also
activate Brk.
MSP expression has recently been implicated as a dri-
ver of breast cancer metastasis and is a marker of poor
prognosis [36]. To test the specificity of Brk action in
Ron receptor signaling to cell migration, HaCaT, MDA-
MB-231 and T47D cells were transfected with either
Brk siRNA or control siRNA. Boyden chamber migra-
tion assays were again performed in which cells were
treated with either vehicle control, MSP or HGF
Figure 3 Signaling specificity of Brk-dependent cell migration.
HaCaT (a), MDA-MB-231 (b) and T47D (c) cells were transiently
transfected with non-targeting (control) siRNA or Brk siRNA and
either vehicle (water) or 50 ng/ml HGF was used as the
chemoattractant for each Boyden chamber migration assay. As
described in the Materials and Methods, migration assays were
performed for 6 hr. A concentration of 20 ng/ml EGF was used as a
positive control chemoattractant for migration. Error bars indicate
the mean (plus standard deviation) of triplicate measures of cell
migration. Single asterisks (*) denote significance (P < 0.05)
determined by an unpaired Student’s t-test between vehicle and
HGF treated cells expressing control siRNA. Double asterisks (**)
denote significance between control and Brk siRNA with either HGF
or EGF used as chemoattractants. Results were confirmed in three
independent experiments.
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Page 6 of 15Figure 4 Intact Met signaling in T47D cells. (a) Real-time quantitative RT-PCR was performed to determine the mRNA expression levels of
Met and Ron receptors in T47D, MDA-MB-231, and HaCaT cells. Error bars indicate the mean (plus standard deviation) of Met and Ron mRNA,
normalized to b-actin, measured in triplicate cultures. Results were confirmed in three independent experiments. Met protein levels in all three
cell lines as measured by Western blotting (insets) (b) T47D, HaCaT and MDA-MB-231 cells were serum-starved for 24 hr and then treated with
50 ng/ml HGF or 80 ng/ml MSP for 5 to 90 min. Western blot analyses were performed on whole cell lysates using ERK5-specific phospho- and
total antibodies. ERK1/2 protein expression was used as a loading control. (c) T47D cells were serum-starved for 24 hr then treated with 20 or 50
ng/ml HGF for 10 min. Whole cell lysates were subjected to Brk immunoprecipitation and in vitro kinase assay using purified recombinant Sam68
as described in Material and Methods.
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allel experiments (insets toF i g u r e s5 b - d )t om e a s u r e
ERK5 activation (as indicated by gel upshift of a portion
of total ERK5) in response to MSP (15 min). In both
HaCaT and MDA-MB-231 cells (Figures 5b and 5c),
MSP did not increase cell migration above basal levels.
In contrast to our results with HGF, there were no dif-
ferences observed with MSP-treated cells expressing
control or Brk siRNA. Consistent with our above data
(Figure 4b), MSP also failed to activate ERK5 relative to
HGF in these two cell lines (Figures 5a and 5b, insets).
In contrast, MSP both activated ERK5 (inset; and as in
Figure 4b) and increased T47D cell migration above
basal levels (Figure 5d). MSP-induced T47D cell migra-
tion was attenuated in Brk siRNA expressing cells.
Expression of Brk siRNA again blocked HGF-induced
cell migration in all three cell lines (as in Figure 3).
Note that MSP can activate Brk in HaCaT cells, but it
does not activate ERK5, nor do these cells migrate in
response to this ligand. Taken together, these results
indicate a linkage between Met/Ron signaling to Brk
and the ability of a given ligand (HGF or MSP) to acti-
vate ERK5 in cell migration.
HGF-induced cell migration requires ERK5 in breast
cancer cells
Growth factor stimulation of breast cancer cells has
been shown to alter Brk-protein complexes with signal-
ing molecules [16,24]. To examine whether Brk and
ERK5 are associated downstream of Met receptor activa-
tion by HGF, HaCaT and MDA-MB-231 cells were trea-
ted with HGF for 15-30 min (Figure 6a). ERK5 was
immunoprecipitated from whole cell lysates using
ERK5-specific antibodies. ERK5 immunoprecipitates
were then subjected to Western blotting with Brk-speci-
fic antibodies. Endogenous Brk was present in ERK5
immunoprecipitates but was not found in IgG controls.
In HaCaT cells, Brk and ERK5 interaction increased in a
time-dependent manner and became readily detectable
at 30 min of HGF treatment. Notably, in MDA-MB-231
cells, we also detected an HGF-regulated interaction
between Brk and ERK5 following at least 30 min of
HGF treatment. To test the requirement for Brk kinase
activity in the Brk/ERK5 interaction, Brk-null COS-1
cells were transiently transfected with flag-tagged wt or
kinase-dead (km) Brk (Figure 6b). ERK5 was again
immunoprecipitated and Brk was visualized using Flag-
specific antibodies. Notably, weak Brk and ERK5 asso-
ciation occurred following either vehicle or HGF treat-
ment of wt- and km-Brk-expressing cells (lanes 3-6).
Increased levels of km-Brk-flag were detected in ERK5
immunoprecipitates relative to wt-Brk-flag (compare
lanes 5-6 to lanes 3-4). Interestingly, in COS-1 cells,
decreased levels of Brk were also detected in ERK5
Figure 5 Brk mediates cell type-specific Met and Ron receptor
signaling to cell migration. (a) In vitro kinase assays were
performed in HaCaT cells as previously described. Cells were serum-
starved for 24 hr then treated with either vehicle (water), MSP (80
ng/ml), HGF (50 ng/ml), or heregulin (25 ng/ml) for 15 min. Purified
recombinant Sam68 was used as a substrate to measure Brk kinase
activity. IgG control images were derived from the same
experiment, Western blot, and film exposure time as the
experimental lanes shown. Boyden chamber migration assays were
performed in HaCaT (b), MDA-MB-231 (c), and T47D (d) cells
expressing non-targeting (control) siRNA or Brk siRNA. Cells were
treated with either vehicle (water) or 80 ng/ml MSP as the
chemoattractant (in the lower chamber). 50 ng/ml HGF was used as
a positive control chemoattractant for migration. Error bars indicate
the mean (plus standard deviation) of triplicate measures of cell
migration. Single asterisks (*) denote significance (P< 0.05)
determined by an unpaired Student’s t-test between vehicle and
HGF or MSP treated cells expressing control siRNA. Double asterisks
(**) denote significance between control and Brk siRNA with either
HGF or MSP used as chemoattractants. Results were confirmed in
three independent experiments. Cells treated at various time points
with 80 ng/ml MSP were subjected to Western blotting with total
ERK5 specific antibody. HGF treatment was used as a positive
control for ERK5 activation (insets).
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lanes 3-4 to lanes 5-6). These results are in contrast to
the behavior of endogenous protein partners above (Fig-
ure 6a) but reminiscent of previous studies reporting
the disassociation of Brk/AKT protein complexes in
response to EGF treatment of HaCaT and COS-1 cells
[24]. Similarly, Lukong et al. [16] recently reported a
transition of Brk-protein complexes from large to small
molecular weight upon EGF stimulation of Brk-positive
BT-20 breast cancer cells. Taken together, these results
suggest that Brk/ERK5 complexes are regulated by HGF
in cells expressing endogenous proteins; Brk complex
formation is likely cell type-dependent and may be
altered by Brk overexpression.
We previously identified an important role for Brk in
EGF- and heregulin- induced ERK5 activation in T47D
breast cancer cells [25]. In addition, ERK5 activation has
been shown by other groups to be associated with pros-
tate cancer cell migration [37,38]. Because our studies
place Brk signaling upstream of ERK5 activation in
response to HGF (Figure 2), and these proteins associate
upon HGF treatment (Figure 6), we wanted to further
investigate the role of ERK5 signaling downstream of
Met receptor activation. To test the requirement of
ERK5 in HGF-induced cell migration, we again per-
formed Boyden chamber migration assays in which cells
were transiently transfected with ERK5 or negative con-
trol siRNA. Serum-starved HaCaT and MDA-MB-231
cells were treated with vehicle or HGF. Interestingly, in
HaCaT cells (Figure 7a), we observed an increase in
HGF-induced cell migration of cells expressing ERK5
siRNA relative to control siRNA, whereas HGF-induced
MDA-MB-231 cell migration was completely blocked by
ERK5 siRNA (Figure 7b). ERK5 was rapidly activated by
HGF (15 min), and ERK5 expression was effectively
silenced in both cell models (insets).
We were surprised to observe increased HGF-induced
HaCaT cell migration upon ERK5 knockdown. However,
MAPK pathways are known to be quite flexible, and
Figure 6 HGF-induced cell migration requires Brk/ERK5
complexes in breast cancer cells. (a) HaCaT and MDA-MB-231/
(231) cells were treated with either vehicle or HGF for 15-30 min (30
min for 231 cells). ERK5 was immunoprecipitated from whole cell
lysates using total ERK5-specific antibodies. ERK5
immunoprecipitates were then subjected to Western blotting with
Brk-specific antibodies. Lysates (10% input) were Western blotted
with total ERK5 and Brk-specific antibodies. (b) COS cells were
transiently transfected with flag-tagged pCMV (vector), wt or kinase
dead (km) Brk. ERK5 was immunoprecipitated from whole cell
lysates using ERK5-specific antibodies and Brk was identified using
flag-specific antibodies. Lysates (10% input) were Western blotted
with flag antibody to indicate the efficiency of ERK5/Brk co-
association.
Figure 7 HGF-induced cell migration requires ERK5 in breast
cancer cells. Boyden chamber migration assays were performed on
HaCaT (a) and MDA-MB-231 (b) cells as previously described. Cells
were transiently transfected with either non-targeting (control)
siRNA or ERK5 siRNA. Lower chambers were supplemented with
either vehicle (water) or 50 ng/ml HGF as the chemoattractant.
Boyden chamber migration assays were performed for 6 hr. Error
bars indicate the mean (plus standard deviation) of triplicate
measures of cell migration. Single asterisks (*) denote significance
(P < 0.05) determined by an unpaired Student’s t-test between
vehicle and HGF treated cells expressing control siRNA. Double
asterisks (**) denote significance between control and ERK5 siRNA
with HGF used as the chemoattractant. Results were confirmed in
three independent experiments. Cells treated for 15 min with HGF
were subjected to Western blotting; ERK5 activation and protein
expression were determined using total ERK5 specific antibodies
(insets).
Castro and Lange Breast Cancer Research 2010, 12:R60
http://breast-cancer-research.com/content/12/4/R60
Page 9 of 15there is the potential for extensive cross-talk between
MAPK modules [39]. To investigate whether decreased
expression of ERK5 induced compensatory activation of
other closely related MAPKs, we measured total and
phospho-ERK1/2 in HaCaT cells following expression of
either control or ERK5 siRNA and short-term treatment
with HGF (Figure 8a). As we suspected, HGF (15 min)
induced more robust activation of ERK1/2 in HaCaT
cells expressing ERK5 siRNA relative to cells expressing
control siRNA. ERK2 (p42) was weakly active in the
complete absence of growth factor stimulation (lane 5).
No changes in JNK or p38 MAPK were observed under
the same conditions (not shown). The Mek inhibitor,
U0126 (5 μM), was included to demonstrate efficient
inhibition of ERK1/2 signaling in these conditions. Total
ERK5 levels indicated effective knockdown, while total
ERK1/2 served as a loading control.
We again performed Boyden chamber migration
assays in HaCaT cells expressing either control siRNA
or ERK5 siRNA. In this set of experiments, we included
U0126 (5 μM) in the top and bottom chambers for sus-
tained ERK1/2 inhibition. This inhibitor also targets
MEK5, leading to ERK5 inhibition [40]. Control siRNA-
and ERK5 siRNA-expressing cells were treated with or
without HGF in the presence or absence of U0126. As
previously observed, ERK5 siRNA-expressing cells trea-
ted with HGF demonstrated increased migration relative
to cells expressing control siRNA (Figure 8b). Interest-
ingly, when pretreated with U0126, cell migration was
attenuated back to basal levels in cells treated with HGF
and expressing either control siRNA or ERK5 siRNA.
Taken together, these results demonstrate a requirement
for ERK5 in HGF-induced breast cancer cell migration.
Keratinocytes are capable of switching from ERK5 to
the closely related MAPKs, ERK1/2, when ERK5 protein
levels are greatly reduced; this alternate pathway is
apparently not employed by ERK5-deficient MDA-MB-
231 cells. Indeed, we observed no changes in HGF-
induced ERK1/2 activation upon ERK5 knockdown in
MDA-MB-231 cells (Figure 8c).
Brk kinase activity is not required for HGF-induced cell
migration
Previous work demonstrated the ability of kinase inac-
tive Brk to promote breast cancer cell proliferation, indi-
cating that Brk functions in part by acting as a scaffold
or adaptor molecule for active signaling complexes [41].
To test the requirement for Brk kinase activity relative
to its domain structure downstream of Met receptor
activation and cell migration, we performed experiments
to rescue Brk knockdown. In these experiments, HaCaT
and MDA-MB-231 cells were transiently transfected
with either control or Brk siRNA targeting the 3′-UTR
of Brk mRNA. Targeting the Brk 3′-UTR was effective
in silencing native Brk mRNA, while not recognizing
flag-tagged wt or kinase-inactive (km) mutant Brk tran-
scripts (i.e., lacking the Brk 3′- U T R )t h a tw e r et r a n s i -
ently coexpressed. Thus, cells transiently expressed
either flag-tagged wt-Brk or km-Brk, while silencing of
Figure 8 ERK5 siRNA expressing cells signal to ERK1/2 to
mediate HGF-induced cell migration in HaCaT cells. (a) HaCaT
cells expressing non-targeting (control) siRNA or ERK5 siRNA were
pre-treated for 30 min with 5 μM U0126, then treated for 15 min
with HGF and Western blot analysis was performed using phospho-
and total-specific antibodies specific for ERK1/2 or total ERK5. (b)
Boyden chamber migration assays were performed using HaCaT
cells expressing either non-targeting (control) siRNA or ERK5 siRNA.
Cells were treated with either vehicle (water) or 50 ng/ml HGF and
in the presence or absence of 5 μM U0126 in the lower and upper
chambers. Error bars indicate the mean (plus standard deviation) of
triplicate measures of cell migration. Single asterisks (*) denote
significance (P< 0.05) determined by an unpaired Student’s t test
between vehicle and HGF treated conditions in either control or
ERK5 siRNA expressing cells. Results were confirmed in three
independent experiments. (c) MDA-MB-231 cells were transiently
transfected with control siRNA or ERK5 siRNA. Cells were serum
starved for 24 hr and then treated with vehicle or HGF at 15 min.
Whole cell lysates were subjected to Western blotting with total-
ERK5, phospho-ERK1/2 or total-ERK1/2 antibodies. ERK1/2 protein
expression served as a loading control.
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tern blot analysis demonstrated that endogenous Brk
expression levels were reduced, while wt- and km-Brk
(both flag-tagged) were expressed appropriately in either
HaCaT or MDA-MB-231 cells; total ERK5 levels
remained similar throughout these manipulations (Fig-
ure 9a). Boyden chamber migration assays were then
performed as previously described using HGF as the
chemoattractant for HaCaT and MDA-MB-231 cells
(Figures 9b and 9c). Consistent with the above results
for Brk siRNA pools targeting the Brk open reading
frame (Figure 3), and in contrast to cells expressing con-
trol siRNA, HaCaT cells expressing Brk 3′-UTR siRNA
failed to migrate in response to HGF. Interestingly,
HGF-induced cell migration was fully rescued in cells
gene-silenced for endogenous Brk, and reexpressing
either wt-Brk or km-Brk (Figures 9b and 9c). Remark-
ably, although cell migration was still regulated by HGF,
these results demonstrate that Brk kinase activity is not
required for this process, but rather Brk domain struc-
ture or scaffolding actions appear to be important
(Figures 9b and 9c).
To further confirm that HGF-induced cell migration
occurs independently of Brk kinase activity, we tested
the migratory status of MDA-MB-435 cells, a Brk-null,
Met-positive breast cancer cell line with similarity to
melanoma [42]. MDA-MB-435 cells were transiently
transfected with either wt- or km-Brk and treated with
HGF in 6-hr migration assays as above. These cells were
weakly migratory in response to HGF alone (Figure
10a). FBS was included as a positive control for robust
migration. Similar to our results with Brk rescue (Figure
9), HGF-induced MDA-MB-435 cell migration increased
upon expression of either wt or km-Brk. In both condi-
tions, Brk expression appeared to constitutively activate
ERK5 relative to vector controls as indicated by gel
upshift (Figure 10b). The MEK inhibitor, U0126, when
a d d e da tc o n c e n t r a t i o n si n t e n d e dt oi n h i b i tE R K 5
(10 μM), blocked wt and km-Brk-induced cell migration
(not shown). These results indicate that the kinase activ-
ity of Brk is not required for Met receptor induced cell
migration. Instead, our data suggest that Brk domain
structure acts to recruit activated ERK5, and that both
proteins are key determinants of HGF-induced cell
migration.
Discussion
Recent reports have shown Brk activation and the exis-
tence of Brk-dependent pathways in response to EGF,
heregulin, and calcium signaling [25,43,44]. Brk asso-
ciated with insulin-receptor substrate-4, and IGF-1 sti-
mulated Brk phosphorylation in HEK-293 cells [18].
However, IGF-1 failed to increase the level of Brk phos-
phorylation or activate Brk kinase activity in T47D
breast cancer cells [25]; IGF-1 effects may have gone
undetected due to high basal Brk activity in these cells
(Fig. 1C). Herein we sought to investigate other Brk-
dependent growth factor-induced pathways crucial for
processes related to breast cancer progression. We iden-
tified HGF and MSP, ligands for Met and Ron receptors,
Figure 9 Brk kinase activity is not required for HGF-induced
cell migration. (a) HaCaT and MDA-MB-231 (231) cells were
transiently cotransfected with non-targeting (control) siRNA or Brk
siRNA targeting the 3′-UTR of Brk mRNA and flag-tagged pCMV
(vector), wt-Brk, or km-Brk. Western blot analysis was performed
using total ERK5 and Brk-specific antibodies to identify endogenous
Brk and flag-tagged Brk. p38 MAPK protein was used as a loading
control. Boyden chamber migration assays were performed in
HaCaT (b) and MDA-MB-231 (c) cells transiently coexpressing
nontargeting siRNA or Brk 3′-UTR siRNA and either flag-tagged
pCMV, wt-Brk, or km-Brk. Vehicle (water) or 50 ng/ml HGF were
used as chemoattractants in the lower chamber. Error bars indicate
the mean (plus standard deviation) of triplicate measures of cell
migration. Single asterisks (*) denote significance (P< 0.05)
determined by an unpaired Student’s t-test between vehicle and
HGF treated conditions in either control or Brk 3′-UTR siRNA cells
coexpressing wt- or km-Brk. Results were confirmed in three
independent experiments.
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activity (Figures 1 and 5). In HGF-treated cells, we
observed phosphorylation and activation of downstream
kinases, including AKT, ERK1/2 and ERK5. However,
following Met receptor activation, Brk acts primarily as
an upstream input to ERK5 activation (Figure 2), med-
iating increased cell migration (Figures 3 and 7). Related
to our work, Lukong and Richard [45] identified KAP3A
(kinase-associated protein 3A) as a Brk substrate impor-
tant for breast cancer cell migration. Notably, Brk kinase
activity is not required for Brk/ERK5 interaction (Figure
6), nor HGF-induced migration upon Brk knockdown
(Figure 9), or induction of migration in Brk-null cells
(Figure 10). Taken together, our data suggest that Brk,
acting via its domain structure or scaffolding function,
may coordinate ERK5-containing signaling complexes
required for HGF-induced cell migration (Figure 7).
Interestingly, these complexes may contain multiple sig-
naling molecules and can switch to ERK1/2 dependency
in HaCaT cells expressing ERK5 siRNA, allowing
increased migration to occur and enhancing ERK1/2
activation in the presence of HGF (Figure 8). Similar to
our studies, sustained Erk1/2 activation was found to
mediate epithelial cell “sheet” migration during wound
healing in the Madin-Darby canine kidney (MDCK cell)
model [46]. This alternate pathway is not observed in
MDA-MB-231 cells upon ERK5 gene silencing (Figure
8c), perhaps revealing a vulnerability of breast cancer
cells that may depend upon Brk/ERK5 complexes for
their increased mobility.
Brk is a key player of Met receptor signaling upstream
of ERK5, also known as BMK1 (big mitogen-activated
kinase 1). Little is known about ERK5, the terminal Ser/
Thr kinase of a three-kinase cascade activated by MEK5
downstream of MEKK2/MEKK3 [47]. These kinases
associate via PD1-domain interactions present on both
classes of kinase (MEKK and MEK). While ERK5 is
believed to be exclusively activated by MEK5-dependent
phosphorylation events, MEKK2/3 and MEK5 are sensi-
tive to a variety of regulatory interactions and signaling
pathway inputs [48,49]. Similar to other MAPK mem-
bers, ERK5 is known to be involved in differentiation,
proliferation, survival and development [50]. ERK5 can
be activated by various stimuli such as stress, growth
factors, mitogens, receptor tyrosine kinases and G pro-
tein-coupled receptors. Studies have associated the dys-
regulation of ERK5 with several human cancers; recent
clinical studies have implicated elevated ERK5 in inva-
sive breast cancer [32]. Our data demonstrate the ability
of Brk and ERK5 to form a complex in HaCaT and
MDA-MB-231 cells (Figure 6a). This endogenous inter-
action appears to be regulated in an HGF-induced man-
ner. Brk/ERK5 complex formation occurs when ERK5 is
activated in both keratinocytes and breast cancer cells;
however, weak basal complex association was detected
in COS-1 cells (Figure 6b). It is possible that several
proteins are coassociated with Brk and Erk5 [16,24]; stu-
dies to further characterize additional components of
Brk/Erk5 containing complexes are currently underway.
A correlation exists between constitutively active
ERK5 and overexpression of erbB2 receptors in breast
cancer cells; attenuating ERK5 expression in these cells
results in inhibition of breast cancer cell growth [51].
Recent reports have identified a few ERK5 targets.
These include the structural protein, connexin 43, the
signaling molecule SGK (serum and glucocorticoid-
inducible kinase), and transcription factors of the MEF2
(myocyte enhancer factor 2) and Sap1a (Ets-domain)
families [25]. We showed previously that Brk enhanced
MEF2-induced T47D cell migration in a p38 MAPK-
dependent manner [25]. Our current results show that
Brk also enhances HGF-induced ERK5 activation (Fig-
ures 2 and 10), implicating both kinases (i.e., Brk and
ERK5) downstream of Met receptor signaling in cell
Figure 10 Brk expression enhances MDA-MB-435 cell
migration. (a) MDA-MB-435 cells were transiently transfected with
pRcCMV (vector), wt-, or km-Brk. Boyden chamber migration assays
were performed with cells using either vehicle (water) or 50 ng/ml
HGF as the chemoattractant. A concentration of 20% FBS was
included as a positive control for robust migration. Error bars
indicate the mean (plus standard deviation) of triplicate measures of
cell migration. Single asterisks (*) denote significance (P< 0.05)
determined by an unpaired Student’s t-test between vehicle and
HGF treated conditions. Double asterisks (**) denote significance
between cells expressing vector and wt-Brk with HGF as the
chemoattractant. 20% FBS was used as a positive control
chemoattractant. (b) MDA-MB-435 cells were transiently transfected
with PRcCMV (vector), wt-, or km-Brk. Cells were treated for 15 min
with vehicle (water) or 50 ng/ml HGF. Whole cell lysates were
subjected to Western blotting with total-ERK5, Brk, and total-p38
antibodies. Brk-specific antibodies were used to demonstrate equal
transfection efficiency and total endogenous p38 MAPK served as a
loading control.
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biology related to metastasis.
The data presented here demonstrate that HGF can
induce increased Brk kinase activity (Figure 1). ERK5
activation also clearly required the presence of Brk pro-
tein for signal transduction (Figure 3). As there are no
pharmacologic inhibitors of Brk kinase activity, we per-
formed knockdown and rescue experiments (Figure 9),
or simply expressed Brk in Brk-null breast cancer cells
(Figure 10). Notably, both wt and km-Brk rescued HGF-
induced cell migration (Figure 9) and ERK5 signaling
(Figure 10). Rescued (i.e., Brk expressing) cells also
required HGF for cell migration. That is, Brk expression
did not induce increased cell migration in the absence
of HGF (Figure 9), suggesting that growth factor is
required for protein complex coordination (Figure 6a).
Interestingly, Brk/ERK5 complex formation does not
appear to require Brk kinase activity as measured in
COS-1 cells (Figure 6b) and km-Brk expression was suf-
ficient to activate ERK5 in MDA-MB-435 cells (Figure
10b), suggesting that Brk may act primarily to scaffold
the MEKK2-3/MEK5/ERK5 complex. Thus, it is impor-
tant to assign functions to Brk kinase activity relative to
its domain structure. Our results reveal an essential
function for Brk structure, but not protein kinase activ-
ity, in HGF-induced cell migration. The underlying
mechanisms as to how Brk behaves as a scaffold protein
or what proteins, other than Brk and ERK5, participate
in this complex remain unknown. For example, Brk may
utilize its SH3 and/or SH2 domains, which have been
s h o w nt of u n c t i o ni ns u b s t r a t er e c o g n i t i o n[ 5 2 ] ;B r k
structural requirements necessary for these protein
interactions are likely to be complex, and remain the
topic of a separate study.
In sum, Met overexpression has been linked with poor
clinical outcome and implicated in breast cancer pro-
gression. Specifically, Met signaling pathways have been
shown to increase tumor vasculature and volume, pro-
mote invasion of tumor cells, and increase tumor
growth and survival in mouse models. Thus, it is critical
to identify and target key players downstream of the
Met pathway. These studies prompt further investigation
of Brk and ERK5 as potential targets for the develop-
ment of better treatment strategies for advanced invasive
breast cancer.
Conclusions
We have identified HGF and MSP, ligands for Met and
Ron receptors, respectively, as novel regulators of Brk
kinase activity. Following Met receptor activation, Brk
acts primarily as an upstream input to ERK5 activation,
mediating increased cell migration. Notably, Brk kinase
activity is not required for Brk/ERK5 interaction or
HGF-induced cell migration. We propose that Brk,
acting via its domain structure or scaffolding function,
coordinates activated ERK5-containing signaling com-
plexes required for HGF-induced cell migration. Drugs
that target Brk complex formation or ERK5 kinase activ-
ity may provide effective additions to breast cancer
treatment regimens aimed at blocking metastasis.
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